


PHARMACEUTICAL 2022



Regulus Therapeutics Inc. Rank 258 of 475





PHARMACEUTICAL 2022

Regulus Therapeutics Inc. Rank 258 of 475



The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 134% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is -128%, being 148% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	65,235
Cost of Goods Sold	0
Intangible Assets	83
Liabilities, Current	5,227
Liabilities, Non-Current	8,269
Other Assets	3,136
Other Compr. Net Income	0
Other Expenses	856
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	17,794
Revenues	864
Selling, General and Administrative Expense	10,022

Output Variable	Value in 1000 USD
Assets	68,454
Liabilities	13,496
Expenses	28,672
Stockholders Equity	54,958
Net Income	-27,808
Comprehensive Net Income	-27,808
Economic Capital Ratio	-128%